Author Topic: DEA: Pharmacovigilance: Future Drug Abuse Trends (GABApentinoids & Opioids)  (Read 548 times)

Offline Chip (OP)

  • Server Admin
  • Hero Member
  • *****
  • Administrator
  • *****
  • Join Date: Dec 2014
  • Location: Australia
  • Posts: 5681
  • Reputation Power: 0
  • Chip has hidden their reputation power
  • Gender: Male
  • Last Login:Today at 12:10:22 PM
  • Deeply Confused Learner
source: https://www.raps.org/news-and-articles/news-articles/2018/6/fda-officials-proactive-pharmacovigilance-key-t

see also: https://www.ptcommunity.com/journal/article/full/2018/6/340/big-data-and-pharmacovigilance-data-mining-adverse-drug-events-and

FDA Officials: ‘Proactive’ Pharmacovigilance Key to Identifying Future Drug Abuse Trends

June 1, 2018

Learning from experience gathered during the ongoing opioid epidemic, top US Food and Drug Administration (FDA) officials say that proactive pharmacovigilance techniques will be key to heading off future drug abuse trends.
 
In a perspective in the New England Journal of Medicine published Wednesday, FDA Commissioner Scott Gottlieb, Center for Drug Evaluation and Research (CDER) Director Janet Woodcock and Douglas Throckmorton, deputy center director for regulatory programs at CDER, write that FDA hopes to use pharmacovigilance to “identify emerging trends earlier and intervene more quickly.”
 
To do so, the authors say that FDA will leverage “clinical, epidemiologic, basic science and social science expertise” to interpret data from new and traditional data sources, such as social media sites and adverse event reports.
 
However, one of the challenges to such an approach will be in deciphering between legitimate changes in drug prescribing and use, and increases of abuse and misuse of prescription and over-the-counter drugs.
 
For instance, FDA recently flagged gabapentinoid abuse as an emerging concern in part because prescriptions for gabapentinoids tripled between 2002 and 2015.
 
In an effort to determine whether gabapentinoid abuse was increasing, FDA turned to social media sites such as Facebook, Twitter and Instagram, as well as forums such as Reddit to determine how users were discussing gabapentinoid use.
 
“A preliminary appraisal of social media topics revealed a shift between 2013 and 2017 from a discussion of legitimate gabapentinoid use for pain and seizures to a focus on misuse and abuse,” the authors write.
 
The authors also write that FDA can use its existing adverse event database to look for associations between combinations of drugs and adverse events, such as respiratory depression, in reports that cite both an opioid and a gabapentinoid.
 
“An effective system of pharmacovigilance for drugs such as opioids must include the capacity to determine the reasons behind changing patterns of prescription drug use and to elucidate the dynamics of misuse, abuse, and appropriate changes in prescribing,” they write, noting that FDA has invested “new resources in developing these capabilities.”
« Last Edit: June 02, 2018, 09:46:37 AM by Chip »
Over 90% of all computer problems can be traced back to the interface between the keyboard and the chair !

Offline Mr.pooper

  • Full Member
  • ***
  • Join Date: Sep 2015
  • Location: Another needle in the haystack
  • Posts: 265
  • Reputation Power: 17
  • Mr.pooper is new on the scene.
  • Last Login:November 24, 2018, 07:42:18 PM
source: https://www.raps.org/news-and-articles/news-articles/2018/6/fda-officials-proactive-pharmacovigilance-key-t

see also: https://www.ptcommunity.com/journal/article/full/2018/6/340/big-data-and-pharmacovigilance-data-mining-adverse-drug-events-and

FDA Officials: ‘Proactive’ Pharmacovigilance Key to Identifying Future Drug Abuse Trends

June 1, 2018

Learning from experience gathered during the ongoing opioid epidemic, top US Food and Drug Administration (FDA) officials say that proactive pharmacovigilance techniques will be key to heading off future drug abuse trends.
 
In a perspective in the New England Journal of Medicine published Wednesday, FDA Commissioner Scott Gottlieb, Center for Drug Evaluation and Research (CDER) Director Janet Woodcock and Douglas Throckmorton, deputy center director for regulatory programs at CDER, write that FDA hopes to use pharmacovigilance to “identify emerging trends earlier and intervene more quickly.”
 
To do so, the authors say that FDA will leverage “clinical, epidemiologic, basic science and social science expertise” to interpret data from new and traditional data sources, such as social media sites and adverse event reports.
 
However, one of the challenges to such an approach will be in deciphering between legitimate changes in drug prescribing and use, and increases of abuse and misuse of prescription and over-the-counter drugs.
 
For instance, FDA recently flagged gabapentinoid abuse as an emerging concern in part because prescriptions for gabapentinoids tripled between 2002 and 2015.
 
In an effort to determine whether gabapentinoid abuse was increasing, FDA turned to social media sites such as Facebook, Twitter and Instagram, as well as forums such as Reddit to determine how users were discussing gabapentinoid use.
 
“A preliminary appraisal of social media topics revealed a shift between 2013 and 2017 from a discussion of legitimate gabapentinoid use for pain and seizures to a focus on misuse and abuse,” the authors write.
 
The authors also write that FDA can use its existing adverse event database to look for associations between combinations of drugs and adverse events, such as respiratory depression, in reports that cite both an opioid and a gabapentinoid.
 
“An effective system of pharmacovigilance for drugs such as opioids must include the capacity to determine the reasons behind changing patterns of prescription drug use and to elucidate the dynamics of misuse, abuse, and appropriate changes in prescribing,” they write, noting that FDA has invested “new resources in developing these capabilities.”

FDA is corrupt as fuck if you didnt know. Fuck Dem Asshats
"If only I had checked myself"
-Guy who wrecked himself

Offline limerence

  • Jr. Member
  • **
  • Join Date: Oct 2015
  • Location:
  • Posts: 72
  • Reputation Power: 2
  • limerence is new on the scene.
  • Gender: Male
  • Last Login:July 02, 2018, 06:26:18 PM
  • Our Community Board
The pretty much only gabapentin/lyrica facebook thinktank group with many thousands of members was mysteriously shut down about a month ago.....

FDA, CDC, DEA, CIA.... pathetic

Tags:
 

Related Topics

  Subject / Started by Replies Last post
3 Replies
2328 Views
Last post August 18, 2015, 08:46:28 AM
by theluciddreamers
1 Replies
1320 Views
Last post August 11, 2015, 01:28:18 PM
by makita
0 Replies
855 Views
Last post August 28, 2015, 03:51:59 AM
by Z
0 Replies
1167 Views
Last post August 28, 2015, 07:11:58 PM
by Chip
0 Replies
759 Views
Last post January 18, 2016, 12:04:31 PM
by Z
36 Replies
10053 Views
Last post July 03, 2018, 04:16:50 PM
by Mr.pooper
0 Replies
971 Views
Last post July 07, 2016, 11:38:24 AM
by Chip
12 Replies
3460 Views
Last post March 30, 2017, 10:11:18 PM
by bignasty
18 Replies
4392 Views
Last post September 01, 2018, 12:04:25 PM
by radioactive_man
8 Replies
1776 Views
Last post March 30, 2018, 11:41:47 AM
by limerence




TERMS AND CONDITIONS

In no event will d&u or any person involved in creating, producing, or distributing site information be liable for any direct, indirect, incidental, punitive, special or consequential damages arising out of the use of or inability to use d&u. You agree to indemnify and hold harmless d&u, its domain founders, sponsors, maintainers, server administrators, volunteers and contributors from and against all liability, claims, damages, costs and expenses, including legal fees, that arise directly or indirectly from the use of any part of the d&u site.


TO USE THIS WEBSITE YOU MUST AGREE TO THE TERMS AND CONDITIONS ABOVE



Founded December 2014